MarketPulse
A

$AGIO

2 articles found
2 positive
0 negative
0 neutral
The Motley FoolThe Motley Fool··James Brumley

Agios Pharma Soars 21% on FDA Fast-Track Win for Sickle Cell Drug

Agios Pharmaceuticals surges on FDA accelerated approval for mitapivat sickle cell treatment, enabling faster path to full approval despite company's ongoing losses.
AGIObiotechpharmaceutical
The Motley FoolThe Motley Fool··Andy Gould

Agios Insider Sells $82K in Stock, But RSU Vesting—Not Confidence—Tells Real Story

Agios insider Krishnan sells $82K in shares via routine RSU tax-withholding event. Retains 16,200 unvested RSUs and recent equity grants signal confidence amid PYRUKYND's 86% revenue growth.
XLVAGIOIHEFDA approvalbiotech